April 30, 2025 07:37 AM EDTUpdated 09:45 AM
Deals
Pharma

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

Elizabeth Cairns

Senior biopharma journalist

Kyle LaHucik

Senior Reporter

No­var­tis plans to ac­quire Reg­u­lus Ther­a­peu­tics for $7.00 per share in cash, or $800 mil­lion, the mi­croR­NA spe­cial­ist said Wednes­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Bridge­Bio’s At­tru­by out­per­forms sales ex­pec­ta­tions, shares rise

GSK's sup­ply chain 're­set' af­ter Ha­le­on spin­off to ease tar­iff im­pact, CEO says

Ar­tios drug ex­ploits ‘repli­ca­tion stress’ in can­cer, shrink­ing sub­set of tu­mors in ear­ly study

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Pfiz­er CEO Bourla sug­gests phar­ma tar­iffs will fo­cus on US ad­ver­saries, not al­lies

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times